Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Celltrions Vegzelma becomes Europes top prescribed anticancer drug in two years Celltrions cancer treatment Vegzelma achieves impressive market dominance in Europe within two years ...

Dose-dense AC every 2 weeks (four-times)then dose-dense ABI-007 260 mg/m 2 every 2 weeks (four-times) plus Bevacizumab (10 ... including in combination with trastuzumab, which is in ongoing ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

Samsung Bioepis also has approval for versions of Roche/Novartis' AMD therapy Lucentis (ranibizumab) and two Roche cancer antibodies, Herceptin (trastuzumab) and Avastin (bevacizumab). The ...